首页> 外文期刊>American Journal of Cardiovascular Disease Research >The Role of Calcium-Sensitizer Levosimendan for the Treatment of Heart Failure
【24h】

The Role of Calcium-Sensitizer Levosimendan for the Treatment of Heart Failure

机译:钙增敏剂左西孟旦在心力衰竭治疗中的作用

获取原文
           

摘要

In the treatment of heart failure, clinical signs are low cardiac output, therapy with positive inotropic agents in an acute cardiac care is mandatory. Three classes of inotropic drugs are currently used, including beta-adrenergic agonists (especially dobutamine), phosphodiesterase inhibitors (such as milrinone) and the recently developed calcium sensitizers such as levosimendan. The classic inotropic drugs offer short-term haemodynamic enhancement in heart failure patient and their use has been connected with poor prognosis. The inotropic drugs, the Ca2+-sensitizers, may offer a choice of long-lasting result.
机译:在心力衰竭的治疗中,临床症状是心输出量低,在急性心脏保健中必须使用正性肌力药物进行治疗。目前使用三类正性肌力药物,包括β-肾上腺素能激动剂(尤其是多巴酚丁胺),磷酸二酯酶抑制剂(例如milrinone)和最近开发的钙敏化剂(例如左西孟旦)。经典的正性肌力药物可为心力衰竭患者提供短期的血流动力学增强作用,其使用与不良预后有关。变力药,即Ca2 +增敏剂,可以提供长期效果的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号